Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Type:
Application
Filed:
August 26, 2022
Publication date:
March 23, 2023
Applicants:
YUHAN CORPORATION, JANSSEN BIOTECH, INC.
Inventors:
Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Sol PARK, Heejun KIM, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Tae Kyun KIM, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON
Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
Type:
Grant
Filed:
July 16, 2019
Date of Patent:
March 7, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J. F. Thuring
Inventors:
John Bodek, Kristina Demjanick, Laura Grussendorf, John Jerbasi, Claus Lang, Dominik Lüthy, Peter Hebbeln, Shant Shahinian, Stuti Mehta, Susan Lenk
Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
February 14, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Rhys Salter, Vadim Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
Abstract: Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.
Type:
Grant
Filed:
May 17, 2019
Date of Patent:
February 14, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Matteo Cesaroni, Matthew Loza, Jarrat Jordan, Loqmane Seridi
Abstract: VHH domains that bind to p1gR are described. The VHH domain may compete with IgA binding to p1gR, or alternatively, the VHH domain may compete with IgA binding to p1gR. The VHH domains may be coupled to therapeutic agents so as to facilitate delivery of the therapeutic agent to the mucosal layer via p1gR-mediated transcytosis. The therapeutic agent can be a small molecule, large molecule, or even an antibody.
Type:
Application
Filed:
July 31, 2020
Publication date:
January 19, 2023
Applicant:
JANSSEN BIOTECH, INC.
Inventors:
Rajkumar GANESAN, Bharathikumar Vellalore MARUTHACHALAM, Adam ZWOLAK, Brian GEIST, Xiefan LIN-SCHMIDT, Sathyadevi VENKATARAMANI, Sanjaya SINGH
Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
Type:
Grant
Filed:
November 19, 2019
Date of Patent:
January 10, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
Abstract: A device configured to administer a medication can comprise a lower housing that includes a housing latch. The device can further comprise a needle guard that is movable relative to the lower housing along a first direction from a first position to a second position so as to expose a needle, and an upper housing supported relative to the lower housing. The upper housing can be configured to move with respect to the lower housing along a second direction from a pre-use position to a dispensed position. The housing latch can releasably interfere with the upper housing when the upper housing is in the pre-use position so as to prevent the upper housing from moving toward the dispensed position, and the movement of the needle guard toward the second position, causes the interference to be removed, thereby allowing the upper housing to move toward the second position.
Type:
Grant
Filed:
October 25, 2019
Date of Patent:
January 3, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Lorin Olson, Vaclav Vojan, Juergen E. Pfrang, Peter Krulevitch, Jingli Wang, Nicholas Foley, Mingqi Zhao, Paul Tashjian
Abstract: An image processing method is provided that automatically calculates Body Surface Area (BSA) score using machine learning techniques. A Felzenszwalb image segmentation algorithm is used to define proposed regions in each of a plurality of training set images. The training set images are oversegmented, and then each of the proposed regions in each of the plurality of oversegmented training set images are manually classified as being a lesion or a non-lesion. A Convolutional Neural Network (CNN) is then trained using the manually classified proposed regions in each of the plurality of training set images. The trained CNN is then used on test images to calculate BSA scores.
Type:
Grant
Filed:
December 8, 2020
Date of Patent:
December 27, 2022
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Yanqing Chen, Charles Tang, Ernesto J. Munoz-Elias
Abstract: Methods of analyzing a drug polypeptide conjugate using tandem mass spectrometry involving dual tandem mass tags (TMTs) are described. Provided herein is an integrated method using TMTs to obtain three analytical measurements, termed “triple play”, which enables identification of the drug occupancy, normalization between multiple samples and triggering of additional MS/MS to identify and localize conjugation site(s) of the payload. Also described is a method of multiplexing conjugation reactions in a single run with TMT labeling for enhanced throughput capability, while maintaining the same sensitivity with current mass spectrometry instrumentation.
Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.
Abstract: A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.
Type:
Application
Filed:
April 16, 2021
Publication date:
November 10, 2022
Applicant:
JANSSEN BIOTECH, INC.
Inventors:
Rajkumar GANESAN, Adam ZWOLAK, Jason HO, Natasa OBERMAJER, Michael DIEM, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Theresa MCDEVITT, Fei SHEN
Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
November 8, 2022
Assignee:
Janssen Biotech, Inc.
Inventors:
Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.
Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
Type:
Grant
Filed:
November 22, 2017
Date of Patent:
October 18, 2022
Assignee:
Janssen Biotech, Inc.
Inventors:
Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
Abstract: A method is described for delivering a single domain antibody or a therapeutic molecule from an apical surface of a polymeric immunoglobulin receptor (pIgR)-expressing cell to a basolateral surface of the pIgR-expressing cell comprising contacting the pIgR-expressing cell with the single domain antibody or the therapeutic molecule, wherein the single domain antibody binds to pIgR, and the therapeutic molecule comprises an agent and the single domain antibody. A method is also described for transporting such a therapeutic molecule to systemic circulation or lamina propria or gastrointestinal tract of a subject comprising administering the therapeutic molecule to the subject via oral delivery, buccal delivery, nasal delivery or inhalation delivery.
Type:
Application
Filed:
July 31, 2020
Publication date:
October 13, 2022
Applicant:
JANSSEN BIOTECH, INC.
Inventors:
Rajkumar GANESAN, Bharathikumar Vellalore MARUTHACHALAM, Adam ZWOLAK, Brian GEIST, Xiefan LIN-SCHMIDT, Sathyadevi VENKATARAMANI, Sanjaya SINGH
Abstract: Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
October 11, 2022
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Michael Diem, Francois Gaudet, Ronan McDaid, Priyanka Nair-Gupta